The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Rs. 40 cr buyback, 200% dividend announced
Subscribe To Our Newsletter & Stay Updated
